Antibody Drug Conjugates (ADCs) � Linker and Conjugation Technologies Market, 2019-2030

Mason98707 Jun, 2021Health

With six approved drugs, namely POLIVY? (2019), LUMOXITI? (2018), BESPONSA? (2017), MYLOTARG? (2017, reapproval), KADCYLA? (2013) and ADCETRIS? (2011), and more than 200 in the pipeline (clinical / preclinical stages), antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics.